IP Library Granted Patent US 9,433,626
Granted Patent B2
US 9,433,626 · App. 14/701,244 · Granted Sep 6, 2016

Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,433,626
App. No.
14/701,244
Granted
Sep 6, 2016
Kind
B2
Abstract

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Claims (54)

1. A method of treating schizophrenia in an individual comprising administering to an individual in need thereof an effective amount of a compound of formula (IA):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is H, hydroxyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, perhaloalkyl, acyl, acyloxy, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, C 1 -C 8 perhaloalkoxy, alkoxy, aryloxy, thiol, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl or carbonylalkylenealkoxy, or R 1 and R 2a are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety, or R 1 and R 3a are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety, or R 1 and R 4a are taken together to form an ethylene (—CH 2 CH 2 —) moiety or a propylene (—CH 2 CH 2 CH 2 —) moiety;

each R 2a and R 2b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, hydroxyl, alkoxy, nitro, substituted or unsubstituted amino, acyloxy, acylamino, aryl, heteroaryl, cycloalkyl, or heterocyclyl, or R 2a and R 2b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or R 2a and R 1 are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety, or R 2a and R 3a are taken together to form an ethylene (—CH 2 CH 2 —) moiety or a propylene (—CH 2 CH 2 CH 2 —) moiety, or R 2a and R 4a are taken together to form a methylene (—CH 2 —) moiety or an ethylene (—CH 2 CH 2 —) moiety;

each R 3a and R 3b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, hydroxyl, alkoxy, nitro, substituted or unsubstituted amino, acyloxy, acylamino, aryl, heteroaryl, cycloalkyl, or heterocyclyl, or R 3a and R 3b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or R 3a and R 1 are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety, or R 3a and R 2a are taken together to form an ethylene (—CH 2 CH 2 —) moiety or a propylene (—CH 2 CH 2 CH 2 —) moiety, or R 3a and R 4a are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety;

each R 4a and R 4b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, nitro, substituted or unsubstituted amino, hydroxyl, alkoxy, acyloxy, acylamino, aryl, heteroaryl, cycloalkyl, or heterocyclyl, or R 4a and R 4b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or R 4a and R 1 are taken together to form an ethylene (—CH 2 CH 2 —) moiety or a propylene (—CH 2 CH 2 CH 2 —) moiety, or R 4a and R 2a are taken together to form a methylene (—CH 2 —) moiety or an ethylene (—CH 2 CH 2 —) moiety, or R 4a and R 3a are taken together to form a propylene (—CH 2 CH 2 CH 2 —) moiety or a butylene (—CH 2 CH 2 CH 2 CH 2 —) moiety;

R 5 is H or unsubstituted C 1 -C 8 alkyl;

each X 1 , X 2 and X 3 is independently N, CH or CR 6 ;

each m, n, o and p is independently 0 or 1;

each R 6 is independently hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, substituted or unsubstituted C 1 -C 8 alkoxy, substituted or unsubstituted aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

each R 8a , R 8b , R 8c , R 8d , R 8e , R 8f , R 8g and R 8h is independently H, hydroxyl, alkoxy, halo, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 8 alkenyl, C 1 -C 8 perhaloalkyl, carboxyl, carbonylalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 alkyl substituted with a carbonylalkoxy, carboxyl or acylamino moiety, or is taken together with a geminal R 8(a-h) to form a substituted or unsubstituted methylene moiety or a moiety of the formula —OCH 2 CH 2 O—, or is taken together with a geminal R 8(a-h) and the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or is taken together with a vicinal R 8(a-h) and the carbon atoms to which they are attached to form a substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, or substituted or unsubstituted heterocyclyl moiety, or is taken together with a vicinal R 8(a-h) to form a bond provided that when an R 8(a-h) is taken together with a vicinal R 8(a-h) to form a bond, the geminal R 8(a-h) is other than hydroxyl; and

Q is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, alkoxy, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy, acylamino, or is a group of the formula —CR 9 ═CR 10a R 10b , wherein R 9 is H or a substituted or unsubstituted C 1 -C 8 alkyl and R 10a and R 10b are taken together with the carbon to which they are attached to form a substituted or unsubstituted cycloalkyl, cycloalkenyl or heterocyclyl moiety;

provided that (i) at least one of X 1 , X 2 and X 3 is N or CR 6 , and (ii) when at least one of X 1 , X 2 and X 3 is CH or CR 6 , then provisions (1)-(4) apply:

(1) when each m, n, o and p is 0 and R 5 is H, then Q is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, acyloxy, cyano, alkynyl, acylamino, a group of the formula —CR 9 ═CR 10a R 10b , or amino substituted with one or two substituted or unsubstituted C 1 -C 8 alkyl;

(2) when each m, n, o and p is 0 and R 5 is methyl, then Q is substituted or unsubstituted aryl other than unsubstituted phenyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, alkynyl, aminocarbonylalkoxy, a group of the formula —CR 9 ═CR 10a R 10b , or amino substituted with one or two substituted or unsubstituted C 1 -C 8 alkyl;

(3) wherein at least one of m, n, o and p is 1 and R 5 is H, then Q substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy, acylamino, or is a group of the formula —CR 9 ═CR 10a R 10b ; and

(4) wherein at least one of m, n, o and p is 1 and R 5 is methyl, then Q substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl other than a substituted piperazinyl, aminoacyl, acyloxy, carboxyl, cyano, alkynyl, aminocarbonylalkoxy, acylamino, or is a group of the formula —CR 9 ═CR 10a R 10 b , or amino substituted with one or two substituted or unsubstituted C 1 -C 8 alkyl.

2. The method of claim 1 , wherein the compound is of formula (C1), (C2), (C3), (C4) or (C5):

wherein:

R 1 is H or substituted or unsubstituted C 1 -C 8 alkyl;

R 5 is H or unsubstituted C 1 -C 8 alkyl;

R 6 is H, halo, or substituted or unsubstituted C 1 -C 8 alkyl;

R 8c is H, OH or substituted or unsubstituted C 1 -C 8 alkyl;

R 8d is H or substituted or unsubstituted C 1 -C 8 alkyl, and the bond indicates the presence of either an E or Z double bond configuration;

Y is O or NR 11 ;

each R 11 , R 12a and R 12b is independently H or substituted or unsubstituted C 1 -C 8 alkyl;

each X 1 and X 3 is independently CH or N; and

D is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

provided that when the compound is of the formula (C5), D is other than unsubstituted phenyl.

3. The method of claim 2 , wherein the compound is of the formula (C1).

4. The method of claim 2 , wherein the compound is of the formula (C2).

5. The method of claim 2 , wherein the compound is of the formula (C3).

6. The method of claim 2 , wherein the compound is of the formula (C4).

7. The method of claim 2 , wherein the compound is of the formula (C5).

8. The method of claim 1 , wherein R 1 is H or methyl.

9. The method of claim 1 , wherein R 5 is H or methyl.

10. The method of claim 1 , wherein X 1 is CH.

11. The method of claim 1 , wherein X 3 is CH.

12. The method of claim 1 , wherein R 6 is H, chloro or methyl.

13. The method of claim 12 , wherein R 6 is methyl.

14. The method of claim 3 , wherein R 8c is H, OH or methyl.

15. The method of claim 14 , wherein R 8d is H or unsubstituted C 1 -C 8 alkyl.

16. The method of claim 4 , wherein R 8d is H or methyl.

17. The method of claim 6 , wherein Y is NR 11 .

18. The method of claim 17 , wherein R 11 is H or methyl.

19. The method of claim 17 , wherein each R 12a and R 12b is H.

20. The method of claim 17 , wherein D is selected from the group consisting of phenyl, 4-fluorophenyl, pyridin-4-yl, pyridine-3-yl, 6-methylpyridin-3-yl, thiophen-2-yl, thiazol-2-yl, and 4-phenylthiazol-2-yl.

21. The method of claim 2 , wherein D is selected from the group consisting of 4-fluorophenyl, pyridin-4-yl, pyridine-3-yl, 6-methylpyridin-3-yl, thiophen-2-yl, thiazol-2-yl, and 4-phenylthiazol-2-yl.

22. The method of claim 1 , wherein Q is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

23. A method of treating schizophrenia in an individual comprising administering to an individual in need thereof an effective amount of a compound selected from the group consisting of compounds 2, 5-22, 28-35, 39, 42-44, 47-50, 53-59, 62-65, 68-89, 105-112, 115-117, 119-121, and 149-154;

or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein the compound is selected from the group consisting of compounds 2, 5-22, 28-35, 39, and 42;

or a pharmaceutically acceptable salt thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MEDIVATION PROSTATE THERAPEUTICS, INC.; MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 040181/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2016
From: CHAKRAVARTY, SARVAJIT; HART, BARRY PATRICK
To: MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 038554/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2016
From: JAIN, RAJENDRA
To: MEDIVATION, INC.
Reel/Frame 038554/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2016
From: MEDIVATION, INC.
To: MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 038554/0631 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 4, 2015
From: MEDIVATION TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036553/0925 →